Resmed Inc (RMD) Financial Statements

Resmed's financial quality is strong, aligning with several key criteria in the investment framework. The company is highly profitable, with an operating margin of 32.7% and a profit margin of 27.5%. Its Return on Equity of 24.9% is sustainably high, exceeding the 15-20% threshold for a quality business. Free cash flow generation is robust, with a 5.0% FCF yield indicating healthy conversion of earnings to cash, though the exact FCF margin is not provided to compare against the >10-15% benchmark. The balance sheet is very healthy, with a low Debt/Equity ratio of 0.14, which is well below the 1.0x Debt/EBITDA caution level, suggesting a substantial net cash position. Revenue growth of 11.0% YoY is consistent and positive but falls into a moderate range, below the 20%+ threshold for high-growth companies and potentially indicating a more mature growth trajectory. There is no data provided on gross margin trends or operating leverage to assess margin expansion. Overall, the financial profile is one of a stable, cash-generative business with excellent returns on capital and a fortress balance sheet, but not one experiencing explosive top-line expansion. Analysis based on data as of 2024-05-15.